Related Experiment Video

Updated: Aug 23, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.2K

[Chinese expert consensus on immunotherapy for advanced non-small lung cancer with oncogenic driver mutations (2022

,

    Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]
    |November 1, 2022
    PubMed

    Insights

    Immunotherapy offers new hope for advanced non-small cell lung cancer (NSCLC) patients with oncogenic driver mutations. This expert consensus provides guidance on using immunotherapy for these challenging NSCLC cases.

    Area of Science:

    • Oncology
    • Immunology
    • Genetics

    Context:

    • Non-small cell lung cancer (NSCLC) with oncogenic driver mutations was historically considered unresponsive to immunotherapy.
    • Advances in understanding the immune microenvironment and targeted drug effects are changing this paradigm.
    • Clinical evidence is accumulating to support immunotherapy in this patient population.

    Purpose:

    • To formulate a Chinese expert consensus on the use of immunotherapy for advanced NSCLC patients with oncogenic driver mutations.
    • To provide practical guidance for Chinese clinicians based on current evidence and clinical experience.
    • To address the specific challenges and opportunities of immunotherapy in this NSCLC subgroup.

    Summary:

    • An expert panel reviewed current evidence on the immune microenvironment and clinical studies related to immunotherapy in NSCLC with driver mutations.
    • They developed a consensus statement integrating scientific data with clinical expertise.
    • The consensus focuses on immunotherapy strategies for advanced NSCLC harboring oncogenic driver mutations.

    Impact:

    • To guide clinical decision-making for Chinese oncologists treating advanced NSCLC with driver mutations.
    • To potentially improve treatment outcomes for NSCLC patients with previously "forbidden" mutations.
    • To advance the application of precision medicine in lung cancer immunotherapy.
    Keywords:
    Expert consensusImmunotherapyLung neoplasmsOncogenic driver mutationResistance to targeted therapy

    More Related Videos

    Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence10:29

    Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

    Published on: August 14, 2019

    10.7K
    Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression06:03

    Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

    Published on: January 19, 2019

    17.2K

    Related Concept Videos

    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against...
    7.8K
    Tumor Immunotherapy01:27

    Tumor Immunotherapy

    Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
    639
    Cancer Vaccines01:30

    Cancer Vaccines

    Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
    Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
    488
    Combination Therapies and Personalized Medicine02:50

    Combination Therapies and Personalized Medicine

    Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
    The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
    5.0K